We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Buys Debiopharm’s Xevinapant in Billion Dollar Deal
Merck Buys Debiopharm’s Xevinapant in Billion Dollar Deal
Merck KGaA will pay Switzerland-based Debiopharm up to $1.08 billion (€900 million) for the global rights to Xevinapant, an investigational head and neck cancer treatment.